Predicting In-Hospital Treatment Failure (≤7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids

References

• BuistAS, McBurnieMA, VollmerWM, et al.; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370:741–750.
   PubMed Web of Science ®Google Scholar
• AnthonisenNR, ManfredaJ, WarrenCP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196–204.
   PubMed Web of Science ®Google Scholar
• PapiA, BellettatoCM, BraccioniF, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173:1114–1121.
   PubMed Web of Science ®Google Scholar
• ConnorsAFJr, DawsonNV, ThomasC, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154:959–967.
   PubMed Web of Science ®Google Scholar
• WoutersEF. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respir Med 2003; 97:S51–59.
   PubMed Web of Science ®Google Scholar
• WilkinsonTM, DonaldsonGC, HurstJR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169:1298–1303.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) April 2001 ( Updated 2004). Global Strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Avaible at: http://www.goldcopd.org/uploads/users/files/GOLDWkshp2004Changes.pdf
   Google Scholar
• WoodheadM, BlasiF, EwigS, HuchonG, IevenM, OrtqvistA, SchabergT, TorresA, van der HeijdenG, VerheijTJ; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26:1138–1180.
   PubMed Web of Science ®Google Scholar
• VollenweiderDJ, JarrettH, Steurer-SteyCA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD010257. DOI:10.1002/14651858.CD010257.
   Google Scholar
• NouiraS, MarghliS, BelghithM, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358:2020–2025.
   PubMed Web of Science ®Google Scholar
• LeuppiJD, SchuetzP, BingisserR, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: The REDUCE randomized clinical trial. JAMA 2013; 309:2223–2231.
   PubMed Web of Science ®Google Scholar
• NiewoehnerDE, ErblandML, DeupreeRH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340:1941–1947.
   PubMed Web of Science ®Google Scholar
• SchweigerTA, ZdanowiczM. Systemic corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Am J Health Syst Pharm 2010; 67:1061–1069.
   PubMed Web of Science ®Google Scholar
• AlíaI, de la CalMA, EstebanA, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011; 171:1939–1946.
   PubMed Web of Science ®Google Scholar
• SolerN, EsperattiM, EwigS, et al. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J 2012; 40:1344–1353.
   PubMed Web of Science ®Google Scholar
• StolzD, Christ-CrainM, BingisserR, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131:9–19.
   PubMed Web of Science ®Google Scholar
• DanielsJM, SnijdersD, de GraaffCS, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181:150–157.
   PubMed Web of Science ®Google Scholar
• HosmerD, LemeshowS. Applied Logistic Regression. New York: Wiley, 1989.
   Google Scholar
• ChowAW, HallCB, KleinJO, et al. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl 1:S62–88.
   PubMed Web of Science ®Google Scholar
• DewanNA, RafiqueS, KanwarB, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117:662–671.
   PubMed Web of Science ®Google Scholar
• NiewoehnerDE, CollinsD, ErblandML. Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med 2000; 161:1201–1205.
   PubMed Web of Science ®Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128–1138.
   PubMed Web of Science ®Google Scholar
• SmithJ, WoodcockA. Cough and its importance in COPD. Int J Chron Obstruct Pulmon Dis 2006; 1:305–314.
   PubMedGoogle Scholar
• PepysMB, HirschfieldGM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805–1812.
   PubMed Web of Science ®Google Scholar
• PereraWR, HurstJR, WilkinsonTM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29:527–534.
   PubMed Web of Science ®Google Scholar
• DahlM, VestboJ, LangeP, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:250–255.
   PubMed Web of Science ®Google Scholar
• Ruiz-GonzálezA, LacastaD, IbarzM, et al. C-reactive protein and other predictors of poor outcome in patients hospitalized with exacerbations of chronic obstructive pulmonary disease. Respirology 2008; 13:1028–1033.
   PubMed Web of Science ®Google Scholar
• HurstJR, PereraWR, WilkinsonTM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:71–78.
   PubMed Web of Science ®Google Scholar
• PengC, TianC, ZhangY, et al. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci 2013; 345:190–194.
   PubMed Web of Science ®Google Scholar
• WilsonR, SethiS, AnzuetoA, et al. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect 2013; 67:497–515.
   PubMed Web of Science ®Google Scholar
• WilsonR, AnzuetoA, MiravitllesM, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012; 40:17–27.
   PubMed Web of Science ®Google Scholar
• Ruiz-GonzálezA, GiménezA, Gómez-ArbonésX, et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Respirology 2007; 12:117–121.
   PubMed Web of Science ®Google Scholar
• GrassiC, CasaliL, CurtiE, et al.; SMART Study Group. Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite Cronica. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002; 14:597–608.
   PubMed Web of Science ®Google Scholar
• WilsonR, AllegraL, HuchonG, et al.; MOSAIC Study Group. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125:953–64.
   PubMed Web of Science ®Google Scholar
• PetitpretzP, ChonéC, Trémolières F; Investigator Study Group. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents 2007; 30:52–59.
   PubMed Web of Science ®Google Scholar
• AgustíA, EdwardsLD, RennardSI, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7:e37483.
   PubMed Web of Science ®Google Scholar